Risperdal,reminyl
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Dementia
Conditions
Dementia, Alzheimer's Disease
Trial Timeline
— → —
NCT ID
NCT00626613About Risperdal,reminyl
Risperdal,reminyl is a approved stage product being developed by Johnson & Johnson for Dementia. The current trial status is unknown. This product is registered under clinical trial identifier NCT00626613. Target conditions include Dementia, Alzheimer's Disease.
What happened to similar drugs?
6 of 20 similar drugs in Dementia were approved
Approved (6) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00626613 | Approved | UNKNOWN |
Competing Products
20 competing products in Dementia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 3 | 26 |
| AL001 + Placebo + Open label - AL001 | Alector | Phase 3 | 22 |
| AL001 | Alector | Phase 2 | 25 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 17 |
| IGC AD1 + Placebo | IGC Pharma | Phase 1 | 19 |
| E2020 + Placebo | Eisai | Approved | 43 |
| ARICEPT | Eisai | Phase 3 | 40 |
| Rasagiline | Eisai | Phase 2 | 35 |
| Donepezil Hydrochloride | Eisai | Pre-clinical | 26 |
| donepezil hcl | Eisai | Phase 3 | 40 |
| Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo | Eisai | Phase 3 | 40 |
| E2020 + E2020 | Eisai | Phase 2 | 35 |
| donepezil hydrochloride (Aricept) | Eisai | Approved | 43 |
| 3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo | Eisai | Phase 2 | 35 |
| E2020 + E2020 | Eisai | Phase 3 | 40 |
| Irsenontrine + Placebo | Eisai | Phase 2 | 35 |
| E2020 | Eisai | Phase 2 | 35 |
| Mecobalamin | Eisai | Approved | 43 |
| E2020 + Placebo | Eisai | Phase 3 | 40 |
| Donepezil Hydrochloride | Eisai | Phase 3 | 40 |